Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — Q3 2020 Earnings Presentation
19 slides from Hyphens Pharma International's earnings presentation, Nov 16, 2020
Slide 1: General Announcement: Results Briefing 3Q2020
11/16/2020 General Announcement::RESULTS BRIEFING 3Q2020 GENERAL ANNOUNCEMENT::RESULTS BRIEFING 3Q2020 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Title Gene
Slide 2: Hyphens Pharma International Limited Results Briefing 3Q2020
HYPHENS PHARMA INTERNATIONAL LIMITED Results Briefing 3Q2020
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Agenda
AGENDA 1. Financial Results 2. Business Update
Slide 5: Financial Results
FINANCIAL RESULTS Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 6: Financial Statement
1 FINANCIAL STATEMENT 1Q2020 2Q2020 3Q2020 3Q2019 9M2020 9M2019 Change S$'000 S$'000 S$'000 S$'000 S$'000 S$'000 % Revenue 31,441 30,199 31,436 30,699 93,076 86,705 7.3% Cost of sales (20,539) (19,996) (21,089) (19,826) (61,624) (56,208) 9.6% Gross profit 10,902 10,203 10,347 10,873 31,452 30,497 3.
Slide 7: Revenue by Business Segment
2 REVENUE BY BUSINESS SEGMENT 51% 54% 55% 57% 49% 53% 54% 13% 12% 12% 12% 15% 15% 14% 36% 34% 33% 31% 36% 32% 32% 1Q2019 2Q2019 3Q2019 4Q2019 1Q2020 2Q2020 3Q2020 Specialty 13,836 15,634 16,900 18,782 15,383 16,025 16,956 Proprietary 3,426 3,638 3,589 3,821 4,655 4,512 4,411 Hypermart 9,742 9,730 10
Slide 8: Gross Profit
3 GROSS PROFIT S$'000 1Q2020 2Q2020 3Q2020 3Q2019 9M2020 9M2019 Gross profit 10,902 10,203 10,347 10,873 31,452 30,497 Addback: PPE NRV adjmt - 330 80 - 410 - Normalised gross profit 10,902 10,533 10,427 10,873 31,862 30,497 Normalised GPM 34.7% 34.9% 33.2% 35.4% 34.2% 35.2% Higher Proprietary Hyper
Slide 9: Operating Expenses
3 OPERATING EXPENSES + Distribution costs: consistent at approx. 20% of revenue + Admin expenses: higher in 3Q2020 due to higher R&D costs + Other losses in 3Q2020 were mainly: + FX losses S$217k, due to strengthening of EUR vs SGD and weakening of local currencies like IDR vs SGD + Prov for stock o
Slide 10: Profit Margins
4 PROFIT MARGINS 36.0% 35.0% 34.0% 33.0% 32.0% 31.0% Negative impact from FY2017 FY2018 FY2019 9M2020 GP margin 32.8% 33.7% 35.7% 33.8% COVID-19 in 9M2020 7.0% • NRV w/d on PPE -S$0.4m 6.0% • Prov for test kits -S$0.3m 5.0% • Prov on other stocks due to 4.0% lower demand -S$0.3m FY2017 FY2018 FY2019
Slide 11: Financial Position
5 FINANCIAL POSITION S$’000 30 Sep 2020 31 Dec 2019 Total assets 88,509 80,131 Inventories 19,273 11,431 Trade & other receivables 32,979 28,654 Cash & cash equivalents 22,505 26,165 Total liabilities 42,388 36,055 Trade & other payables 37,093 30,628 Bank borrowings 410 300 Total equity 46,121 44,0
Slide 12: Business Update
BUSINESS UPDATE Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 13: New Distributor for Ceradan
NEW DISTRIBUTOR FOR CERADAN® + Appointment of Shanghai Good Luck 上海古腊国际贸易有限公司 海古腊国际贸易有限公司 as exclusive distributor of Ceradan® in Mainland China Virtual signing ceremony on 12 Nov 2020
Slide 14: New Distributors for Ocean Health
NEW DISTRIBUTORS FOR OCEAN HEALTH® + Appointment of Healthguard Pharmacy Limited as exclusive distributor of Ocean Health® in Sri Lanka + Appointment of SUTL HK as exclusive distributor of Ocean Health® supplements in Hong Kong, Macau and Duty-Free Channels in China
Slide 15: Ceradan Facelift
ie oe @ REPEC ) ~ Fete eres tuppeind & ») Ti at le loti ly 4 Mel mj muepesso 6 ge WA | || isi = (( Pec = ue — Lu a Le = <x a <x o Lu oO Moisturising Wash
Slide 16: Ocean Health New Launch
OCEAN HEALTH MOVING = cS prink up for muscle strength; Convenient Powder Sachet
Slide 17: Digital Business
DIGITAL BUSINESS New talents who have joined us to lead new digital initiatives: + Senior Manager, Digital Transformation, Hyphens + Business Development Manager, Pan-Malayan + Associate Business Development Manager & Pharmacist, Pan-Malayan
Slide 18: Questions & Answers
QUESTIONS & ANSWERS Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 19: Hyphens Pharma International Limited (SGX: 1J5)
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — Q3 2020 Earnings Presentation on 6ix